CHEST Physician
-
A visible impact
With the year drawing to a close, it’s the perfect time to look back on the accomplishments of 2024 and discuss what we hope to see in the coming year. Bob Musacchio, PhD, CEO of CHEST, and Bob De Marco, MD, FCCP, Chair of the CHEST Board of Advisors, reflect on CHEST philanthropy.
-
Council of Networks: Reflecting on the success of 2024
Former Council of Networks Chair, Margaret Pisani, MD, MPH, FCCP, provides a short recap of what the Networks accomplished last year.
-
White ribbons around CHEST HQ raise awareness for lung cancer screening and early detection
During the month of November, CHEST displayed white ribbons around its headquarters in Glenview, Illinois, to raise awareness for lung cancer screening and early detection.
-
Top reads from the CHEST journal portfolio – December 2024
Read about nocturnal cardiac arrhythmias, spontaneous breathing trial protocols, and indeterminate lung nodules diagnosis.
-
Biomarker use in ARDS resulting from COVID-19 infection
There is renewed interest in the use of immunomodulatory therapies in patients with acute hypoxemic respiratory failure. Multiple investigations during the course of the pandemic demonstrated that dexamethasone administration improved mortality in patients with severe COVID-19.
-
Should napping be recommended as a health behavior?
The quest for an effective, inexpensive, and manageable intervention for sleep loss often leads to the question: What about naps? Author Sara C. Mednick, PhD, lists the pros and cons.
-
Exciting opportunities for tobacco treatment: Unpacking the CMS changes
Changes enacted by CMS are embedding the integration of tobacco and nicotine addiction treatment more deeply into our nation’s health care system.
-
Top reads from the CHEST journal portfolio – November 2024
Dive into the healthy adherer effect in OSA, ICU stays for asthma, and COPD exacerbations related to medication use frequency
-
Extending exercise testing using telehealth monitoring in patients with ILD
The COVID-19 pandemic revolutionized the use of monitoring equipment in general and oxygen saturation monitoring devices as pulse oximeters in specific. Home technology devices such as home spirometry, smart apps, and wearable sensors combined with patient-reported outcome measures are increasingly used to monitor disease progression and medication compliance in addition to routine physical activity. The increasing adoption…
-
Major takeaways from the seventh world symposium on PH
The core definition of pulmonary hypertension (PH) remains a mean pulmonary arterial pressure (mPAP) > 20 mm Hg, with precapillary PH defined by a pulmonary arterial wedge pressure (PCWP) ≤ 15 mm Hg and pulmonary vascular resistance (PVR) > 2 Wood units (WU), similar to the 2022 European guidelines.1 2 There was recognition of uncertainty…
